Bristol Myers Squibb to leverage Molecular Template platform against multiple cancer targets
Bristol Myers Squibb to leverage Molecular Template platform against multiple cancer targets Texas headquartered Molecular Templates (MTEM) has entered into a worldwide strategic research collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel therapies designed for specific oncology targets. The oncology targets under this partnership and the duration of the alliance with BMS, however, have not been disclosed. The collaboration will seek to discover new molecules utilizing MTEM’s next generation engineered toxin body (ETB) platform...
Source: biopharma-reporter.com